Filter Results:
(898)
Show Results For
- All HBS Web
(1,340)
- People (4)
- News (227)
- Research (898)
- Events (4)
- Multimedia (7)
- Faculty Publications (496)
Show Results For
- All HBS Web
(1,340)
- People (4)
- News (227)
- Research (898)
- Events (4)
- Multimedia (7)
- Faculty Publications (496)
Sort by
- October 2011 (Revised June 2013)
- Case
Novo Nordisk: A Commitment to Sustainability
By: Robert G. Eccles and Michael P. Krzus
The case describes the early commitment of a European pharmaceutical company, Novo Nordisk, to integrated reporting. Novo Nordisk is one of the pioneers of integrated reporting and it emerged out of its commitment to a "Triple Bottom Line approach to managing the... View Details
Keywords: Strategic Planning; Business Ventures; Business or Company Management; Integrated Corporate Reporting; Business Strategy; Pharmaceutical Industry
Eccles, Robert G., and Michael P. Krzus. "Novo Nordisk: A Commitment to Sustainability." Harvard Business School Case 412-053, October 2011. (Revised June 2013.)
- 13 Nov 2012
- First Look
First Look: November 13
finds that academic commentary on the BSC often ignores its role in strategy execution. The paper discusses how the BSC can be used in public sector applications, as well as for companies that want to internalize environmental, social,... View Details
Keywords: Sean Silverthorne
- February 2009 (Revised December 2009)
- Case
Merck: Global Health and Access to Medicines
By: V. Kasturi Rangan and Katharine Lee
The case describes the effort of Merck, a global leader in pharmaceuticals, in making available its medicines to the poor. The challenge for the company (or for that matter, any pharmaceutical company) is how to integrate its business strategy with its corporate social... View Details
Keywords: Globalized Firms and Management; Health Care and Treatment; Emerging Markets; Corporate Social Responsibility and Impact; Poverty; Business Strategy; Pharmaceutical Industry
Rangan, V. Kasturi, and Katharine Lee. "Merck: Global Health and Access to Medicines." Harvard Business School Case 509-048, February 2009. (Revised December 2009.)
- July 2004 (Revised May 2005)
- Case
Pfizer's Virtual CIO (Abridged)
By: F. Warren McFarlan and Brian DeLacey
Discusses the IT organization and IT strategy issues facing Pfizer, one of the world's largest pharmaceutical companies. Managing over $1 billion of IT expense, the company has a committee approach for handling all critical IT decisions, an approach that is consistent... View Details
Keywords: Decision Making; Cost Management; Organizational Culture; Strategy; Information Technology; Pharmaceutical Industry
McFarlan, F. Warren, and Brian DeLacey. "Pfizer's Virtual CIO (Abridged)." Harvard Business School Case 305-018, July 2004. (Revised May 2005.)
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- March 2019
- Case
Dabur India: Growing Professional Management from Family Roots
By: Suraj Srinivasan, Namrata Arora and Jonah Goldberg
The case opens in December of 2018, with Sunil Duggal, the CEO of Dabur India (a multinational consumer goods conglomerate with a focus in Ayurvedic products) contemplating who should succeed him at the head of the company. The new CEO will have been the first since... View Details
Keywords: Family Business; Management Succession; Multinational Firms and Management; Business Growth and Maturation
Srinivasan, Suraj, Namrata Arora, and Jonah Goldberg. "Dabur India: Growing Professional Management from Family Roots." Harvard Business School Case 119-089, March 2019.
- October 2012
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)
By: Toby Stuart and James Weber
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and James Weber. "Sirtris Pharmaceuticals: Living Healthier, Longer (Abridged)." Harvard Business School Case 813-029, October 2012.
- 15 Dec 2009
- First Look
First Look: Dec. 15, 2009
Working PapersThe Global Networks of Multinational Firms Authors:Laura Alfaro and Maggie Chen Abstract In this paper we characterize the topology of global multinational networks and examine the macro and... View Details
Keywords: Martha Lagace
- March 2008 (Revised June 2008)
- Case
Sirtris Pharmaceuticals: Living Healthier, Longer
Describes a set of key strategic decisions facing the scientific founder and CEO of a promising, early stage bio-pharmaceuticals company. Should the company establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel... View Details
Keywords: Business Startups; Decision Choices and Conditions; Entrepreneurship; Growth and Development Strategy; Risk Management; Brands and Branding; Pharmaceutical Industry
Stuart, Toby, and David Kiron. "Sirtris Pharmaceuticals: Living Healthier, Longer." Harvard Business School Case 808-112, March 2008. (Revised June 2008.)
- June 2015
- Case
Ethiopia: An Emerging Market Opportunity?
By: John A. Quelch and Sunru Yong
This case centers on the potential and challenges of entering an emerging market. It provides a brief overview of the Ethiopian market, market reforms and policies, and the business environment faced by foreign companies. Three multinational businesses, CareCo, ShoeCo,... View Details
Quelch, John A., and Sunru Yong. "Ethiopia: An Emerging Market Opportunity?" Harvard Business School Brief Case 915-501, June 2015.
- October 2002
- Teaching Note
Strategy in Emerging Markets (TN)
By: Tarun Khanna
Provides an overview of several cases on multinational and local companies (including business groups) operating in settings in Asia, Africa, Latin America, and worldwide. Also provides a conceptual framework for thinking about these cases and links to related academic... View Details
- March 2014 (Revised December 2014)
- Case
Vision 2020: Takeda and the Vaccine Business
By: John A. Quelch and Margaret L. Rodriguez
In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details
Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Pharmaceutical Industry; Pharmaceutical Industry
Quelch, John A., and Margaret L. Rodriguez. "Vision 2020: Takeda and the Vaccine Business." Harvard Business School Case 514-084, March 2014. (Revised December 2014.)
- 09 Dec 2002
- Research & Ideas
Unilever—A Case Study
This article considers key issues relating to the organization and performance of large multinational firms in the post-Second World War period. Although foreign direct investment is defined by ownership and control, in practice the... View Details
- June 2004
- Case
Aventis SA (A): Planning for a Merger
By: Joshua D. Margolis and Carin-Isabel Knoop
Eight executives at Hoechst and Rhone-Poulenc must make four crucial decisions on the eve of merging their companies to become Aventis--what would become the world's third largest pharmaceutical firm. In addition to formulating a vision and strategy, the two firms must... View Details
Keywords: Problems and Challenges; Mergers and Acquisitions; Horizontal Integration; Organizational Design; Organizational Culture; Pharmaceutical Industry; United States
Margolis, Joshua D., and Carin-Isabel Knoop. "Aventis SA (A): Planning for a Merger." Harvard Business School Case 404-003, June 2004.
- December 2008 (Revised April 2010)
- Case
Proteus Biomedical: Making Pigs Fly
By: Richard G. Hamermesh, Lauren Barley and Ginger Graham
Proteus is a healthcare start-up that has developed technology to embed electronics for computing and sensing in existing medical devices and drugs. The technology could potentially change the basis of competition in the pharmaceutical industry. The company is... View Details
Keywords: Business Startups; Entrepreneurship; Technological Innovation; Rights; Negotiation Deal; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Hamermesh, Richard G., Lauren Barley, and Ginger Graham. "Proteus Biomedical: Making Pigs Fly." Harvard Business School Case 809-051, December 2008. (Revised April 2010.)
- April 2017
- Supplement
Imprimis (C)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case is a supplement to Imprimis (A & B). Set in 2015, it first describes Imprimis’s decision to introduce its own line of compounded eye drop medication called LessDrops. The case then examines the moral dilemma faced by CEO Mark Baum, who was struck by the... View Details
Keywords: Health Care and Treatment; Cost; Moral Sensibility; Competitive Strategy; Decision Choices and Conditions; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (C)." Harvard Business School Supplement 717-497, April 2017.
- June 2007 (Revised September 2021)
- Case
Thomas J. Watson, IBM and Nazi Germany
By: Geoffrey Jones, Grace Ballor and Adrian Brown
Considers the strategy of U.S.-owned IBM, then a manufacturer of punch cards, in Nazi Germany before 1937. Opens with IBM CEO Thomas J. Watson meeting Adolf Hitler in his capacity as President of the International Chamber of Commerce. IBM had acquired a German company... View Details
Keywords: Business History; Values and Beliefs; Multinational Firms and Management; Corporate Social Responsibility and Impact; Investment; Business and Government Relations; Germany; United States
Jones, Geoffrey, Grace Ballor, and Adrian Brown. "Thomas J. Watson, IBM and Nazi Germany." Harvard Business School Case 807-133, June 2007. (Revised September 2021.)
- 17 Jan 2023
- Cold Call Podcast
Nestlé’s KitKat Diplomacy: Neutrality vs. Shared Value
- 2011
- Working Paper
Managing Political Risk in Global Business: Beiersdorf 1914-1990
By: Geoffrey Jones and Christina Lubinski
This working paper examines corporate strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a German-based pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks... View Details
Keywords: History; Risk Management; Business History; Multinational Firms and Management; Corporate Strategy; Intellectual Property; Cooperation; Business and Government Relations; Germany
Jones, Geoffrey, and Christina Lubinski. "Managing Political Risk in Global Business: Beiersdorf 1914-1990." Harvard Business School Working Paper, No. 12-003, July 2011.
- 23 Feb 2004
- Research & Ideas
How Corporate Responsibility is Changing in Asia
To what extent do multinational corporations have an institutional obligation to the Asian countries in which they serve, and does that obligation include holding higher standards than Asian law requires? These questions were debated at... View Details
Keywords: by Julia Hanna